National Institute of Health: New clinical studies on long COVID therapies launched
The National Institutes of Health (NIH) in the USA announce the launch of new clinical studies. They do research on new therapies for the treatment of long COVID complaints. In the RECOVER-VITAL study, for example, a therapy with the drug Paxlovid is being researched. This is a possible therapeutic approach if SARS-CoV-2 viruses remain in the body even after the acute infection has ended. Another example is the RECOVER-NEURO study, in which therapies for impaired mental abilities are being researched, such as web-based training programmes. The RECOVER-SLEEP study aims to do research on possible therapies for sleep disturbances. Among other things, the RECOVER-AUTONOMIC study will do research on therapy for disorders of the circulatory system. A further study will focus on the treatment of stress intolerance and fatigue.
The studies are part of the NIH’s RECOVER (Researching COVID to Enhance Recovery) initiative. This is a national research programme in the USA. It aims to understand, prevent and treat long COVID. The following English-language website of the initiative provides extensive information about the programme: https://recovercovid.org/
Die National Institutes of Health
The National Institutes of Health (NIH) is headquartered in Bethesda (Maryland). It is part of the American Department of Health and Human Services, and encompasses 27 institutes and centres. These attend to basic medical research, clinical research and translational research. They research the causes of diseases, as well as possible treatments and medicines.
The Deutsche Ärzteblatt was started in the year 1872. It is an official organ of the medical profession. It is published by the German Medical Association and the National Association of Statutory Health Insurance Physicians. It is published by the Cologne-based Deutsche Ärzteverlag GmbH, and is its highest-circulation publication.